Principal Scientist Merck & Co. Inc Kenilworth, New Jersey, United States
A panel discussion on the novel modalities would be an interesting conversation. - ADC development - Fc-fusion protein development - PEGylated protein development - Bispecifics and Trispecific constructs
Learning Objectives:
Understand and appreciate differences between different classes of novel modalities
Gather perspectives on how companies deal with development of these unique modalities
Understand what needs to be done differently as compared to antibody development
